WallStSmart

Palantir Technologies Inc. (PLTR)vsVistance Networks, Inc. (VISN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Palantir Technologies Inc. generates 209% more annual revenue ($6.16B vs $1.99B). VISN leads profitability with a 365.4% profit margin vs 49.0%. PLTR appears more attractively valued with a PEG of 1.60. PLTR earns a higher WallStSmart Score of 75/100 (B).

PLTR

Strong Buy

75

out of 100

Grade: B

Growth: 10.0Profit: 10.0Value: 2.7Quality: 9.0
Piotroski: 5/9Altman Z: 4.71

VISN

Buy

62

out of 100

Grade: C+

Growth: 4.7Profit: 6.0Value: 4.0Quality: 6.5
Piotroski: 5/9Altman Z: 0.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

PLTRSignificantly Overvalued (-83.0%)

Margin of Safety

-83.0%

Fair Value

$91.40

Current Price

$167.23

$75.83 premium

UndervaluedFair: $91.40Overvalued

Intrinsic value data unavailable for VISN.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

PLTR6 strengths · Avg: 10.0/10
Market CapQuality
$401.86B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
30.9%10/10

Every $100 of equity generates 31 in profit

Profit MarginProfitability
49.0%10/10

Keeps 49 of every $100 in revenue as profit

Operating MarginProfitability
47.1%10/10

Strong operational efficiency at 47.1%

Revenue GrowthGrowth
92.8%10/10

Revenue surging 92.8% year-over-year

EPS GrowthGrowth
215.4%10/10

Earnings expanding 215.4% YoY

VISN4 strengths · Avg: 10.0/10
Price/BookValuation
0.6x10/10

Reasonable price relative to book value

Profit MarginProfitability
365.4%10/10

Keeps 365 of every $100 in revenue as profit

EPS GrowthGrowth
1697.0%10/10

Earnings expanding 1697.0% YoY

Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

Areas to Watch

PLTR3 concerns · Avg: 2.7/10
PEG RatioValuation
1.604/10

Expensive relative to growth rate

P/E RatioValuation
141.7x2/10

Premium valuation, high expectations priced in

Price/BookValuation
41.1x2/10

Trading at 41.1x book value

VISN4 concerns · Avg: 2.5/10
Market CapQuality
$1.48B3/10

Smaller company, higher risk/reward

Operating MarginProfitability
2.2%3/10

Operating margin of 2.2%

PEG RatioValuation
2.942/10

Expensive relative to growth rate

Revenue GrowthGrowth
-1.4%2/10

Revenue declined 1.4%

Comparative Analysis Report

WallStSmart Research

Bull Case : PLTR

The strongest argument for PLTR centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 49.0% and operating margin at 47.1%. Revenue growth of 92.8% demonstrates continued momentum.

Bull Case : VISN

The strongest argument for VISN centers on Price/Book, Profit Margin, EPS Growth. Profitability is solid with margins at 365.4% and operating margin at 2.2%.

Bear Case : PLTR

The primary concerns for PLTR are PEG Ratio, P/E Ratio, Price/Book. A P/E of 141.7x leaves little room for execution misses.

Bear Case : VISN

The primary concerns for VISN are Market Cap, Operating Margin, PEG Ratio.

Key Dynamics to Monitor

PLTR profiles as a growth stock while VISN is a declining play — different risk/reward profiles.

VISN carries more volatility with a beta of 1.92 — expect wider price swings.

PLTR is growing revenue faster at 92.8% — sustainability is the question.

PLTR generates stronger free cash flow (1.2B), providing more financial flexibility.

Bottom Line

PLTR scores higher overall (75/100 vs 62/100), backed by strong 49.0% margins and 92.8% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Palantir Technologies Inc.

TECHNOLOGY · SOFTWARE - INFRASTRUCTURE · USA

Palantir Technologies Inc. creates and implements software platforms for the intelligence community in the United States to assist in counterterrorism investigations and operations. The company is headquartered in Denver, Colorado.

Visit Website →

Vistance Networks, Inc.

TECHNOLOGY · COMMUNICATION EQUIPMENT · USA

Gyroscope Therapeutics Holdings plc, a clinical-stage gene therapy company, develops gene therapy products to treat patients with eye diseases. The company is headquartered in Stevenage, the United Kingdom.

Want to dig deeper into these stocks?